866-997-4948(US-Canada Toll Free)

House Dust Mite Allergy - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Therapeutic Area

No. of Pages : 49 Pages


Global Markets Direct’s, \'House Dust Mite Allergy - Pipeline Review, H2 2013\', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy. 

House Dust Mite Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for House Dust Mite Allergy.
  • A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the House Dust Mite Allergy pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy Overview
Therapeutics Development
An Overview of Pipeline Products for House Dust Mite Allergy
House Dust Mite Allergy Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
House Dust Mite Allergy Therapeutics – Products under Development by Companies
Companies Involved in House Dust Mite Allergy Therapeutics Development
ALK-Abello A/S
DBV Technologies
Stallergenes S.A.
Torii Pharmaceutical Co., Ltd.
Circassia Holdings Ltd.
Genetic Immunity, LLC
ANERGIS SA
Bial - Portela & Ca, S.A.
Biomay AG
House Dust Mite Allergy – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ToleroMune House Dust Mite T Cell Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mitizax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actair - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DermAll-HDM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
House Dust Mite Peptide Carrier Fusion Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AllerDM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIA-15-2957 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viaskin House Dust Mite - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TO-204 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
House Dust Mite Allergy Therapeutics – Drug Profile Updates
House Dust Mite Allergy Therapeutics – Discontinued Products
House Dust Mite Allergy Therapeutics - Dormant Products
House Dust Mite Allergy – Product Development Milestones
Featured News & Press Releases
Oct 10, 2012: Merck Plans To Initiate Phase III Clinical Trial With HDM AIT In North America
Oct 15, 2011: Circassia Initiates Key Phase II Clinical Trial Of House Dust Mite Allergy Treatment

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products Under Development for House Dust Mite Allergy, H1 2013
Products under Development for House Dust Mite Allergy – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
ALK-Abello A/S, H1 2013
DBV Technologies, H1 2013
Stallergenes S.A., H1 2013
Torii Pharmaceutical Co., Ltd., H1 2013
Circassia Holdings Ltd., H1 2013
Genetic Immunity, LLC, H1 2013
ANERGIS SA, H1 2013
Bial - Portela & Ca, S.A., H1 2013
Biomay AG, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
House Dust Mite Allergy Therapeutics – Drug Profile Updates
House Dust Mite Allergy Therapeutics – Discontinued Products
House Dust Mite Allergy Therapeutics – Dormant Products

List of Chart


Number of Products under Development for House Dust Mite Allergy, H1 2013
Products under Development for House Dust Mite Allergy – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *